Skip to main content
. 2020 Jun 25;10(8):e01665. doi: 10.1002/brb3.1665

Table 2.

Clinical comparison of PNS+ and PNS− pSS patients

Characteristics PNS+, n = 23 PNS−, n = 27 p‐Value
Age (years, mean ± SD) 56.96 ± 11.38 54.81 ± 9.58 .323
First symptoms (year of life, mean ± SD) 45.83 ± 12.56 44.67 ± 11.17 .602
Diagnosis of pSS(year of life, mean ± SD) 53.52 ± 12.11 51.48 ± 11.01 .405
Time to diagnosis (years, mean ± SD) 7.7 ± 5.16 6.81 ± 7.2 .229
Disease duration (years, mean ± SD) 3.65 ± 3.42 3.78 ± 4.03 .938
Xerophthalmia 22 (96%) 27 (100%) .273
Xerostomia 22 (96%) 27 (100%) .273
Parotid enlargement 17 (74%) 12 (44%) .035
Positive Schirmer test 17 (74%) 13 (48%) .061
CNS involvement 7 (30%) 5 (19%) .325
Vasculitis 7 (30%) 4 (15%) .183
Articular involvement 12 (52%) 16 (59%) .614
Gastrointestinal tract involvement 12 (52%) 14 (52%) .981
Cardiovascular system involvement 2 (9%) 3 (11%) .776
Respiratory tract involvement 15 (65%) 10 (37%) .047
Lymphadenopathy 14 (61%) 5 (19%) .002
Lymphoma 2 (9%) 0 (0%) .073
Urinary tract involvement 12 (52%) 13 (48%) .776
Autoimmune thyroid disease 2 (9%) 4 (15%) .502
CNS involvement 7 (30%) 4 (15%) .183
Cyclophosphamide treatment 4 (17%) 0 (0%) .010
Steroid treatment 19 (83%) 18 (67%) .194
ESSDAI (mean ± SD) 7 ± 6.82 4.7 ± 4.58 .245
ESSPRI (mean ± SD) 5.47 ± 1.66 4.82 ± 1.72 .187
SSDDI (mean ± SD) 4.65 ± 2.5 3.04 ± 2.1 .055
ODSS (mean ± SD) 1.78 ± 2.21 0.59 ± 0.93 .083

Abbreviations: CNS, central nervous system; ESSDAI EULAR, Sjögren's Syndrome Disease Activity Index; ESSPRI EULAR, Sjögren's Syndrome Patient Reported Index; ODSS, Overall Disability Sum Score; PNS−, patients without peripheral neuropathy; PNS+, patients with peripheral neuropathy; pSS, primary Sjögren's syndrome; SSDDI, Sjögren's Syndrome Disease Damage Index.

The results with statistical significance p<.05 are shown in bold.